Article
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Cellular oncology (Dordrecht, Netherlands) - 1 Jun 2016
Silva-Oliveira Renato José, Silva Viviane Aline Oliveira, Martinho Olga, Cruvinel-Carloni Adriana, Melendez Matias Eliseo, Rosa Marcela Nunes, de Paula Flávia Escremim, de Souza Viana Luciano, Carvalho André Lopes, Reis Rui Manuel
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) is a member of the HER family of growth factors that activates several intracellular signaling pathways promoting proliferation and survival. EGFR over-expression is frequently associated with gene mutation or amplification, thereby constituting a major target for molecular therapies. Recently, a new generation of EGFR inhibitors has been developed with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.